Increased behavioral and neuronal responses to a hallucinogenic drug in PACAP heterozygous mutant mice

PLoS One. 2014 Feb 20;9(2):e89153. doi: 10.1371/journal.pone.0089153. eCollection 2014.

Abstract

Accumulating evidence from human genetic studies implicates the pituitary adenylate cyclase-activating polypeptide (PACAP) gene as a risk factor for psychiatric disorders, including schizophrenia and stress-related diseases. Mice with homozygous disruption of the PACAP gene display profound behavioral and neurological abnormalities that are ameliorated with the atypical antipsychotic and dopamine D2 and serotonin (5-HT)2 antagonist risperidone and the 5-HT2 receptor antagonist ritanserin; however, the underlying mechanisms remain unknown. Here, we investigated if PACAP heterozygous mutant (PACAP(+/-)) mice, which appear behaviorally normal, are vulnerable to aversive stimuli. PACAP(+/-) mice were administered a 5-HT2 receptor agonist, (±)-2,5-dimethoxy-4-iodoamphetamine (DOI), a hallucinogenic drug, and their responses were compared with the littermate wild-type mice. After DOI injection, PACAP(+/-) mice showed increased head-twitch responses, while their behavior was normal after saline. DOI induced deficits in sensorimotor gating, as determined by prepulse inhibition, specifically in PACAP(+/-) mice. However, other 5-HT2 receptor-dependent responses, such as corticosterone release and hypothermia, were similarly observed in PACAP(+/-) and wild-type mice. c-Fos expression analysis, performed in various brain regions, revealed that the DOI-induced increase in the number of c-Fos-positive cells was more pronounced in 5-HT2A receptor-negative cells in the somatosensory cortex in PACAP(+/-) mice compared with wild-type mice. These results indicate that PACAP(+/-) mice exhibit specific vulnerability to DOI-induced deficits in cortical sensory function, such as exaggerated head-twitch responses and sensorimotor gating deficits. Our findings provide insight into the neural mechanisms underlying impaired behavioral responses in which 5-HT2 receptors are implicated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamines / pharmacology
  • Animals
  • Behavior, Animal / drug effects*
  • Brain / cytology
  • Brain / drug effects
  • Female
  • Gene Expression Regulation / drug effects
  • Hallucinogens / pharmacology*
  • Male
  • Mice
  • Mothers
  • Mutation*
  • Neurons / drug effects*
  • Neurons / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide / genetics*
  • Proto-Oncogene Proteins c-fos / metabolism
  • Receptors, Serotonin, 5-HT2 / metabolism
  • Serotonin 5-HT2 Receptor Agonists / pharmacology

Substances

  • Amphetamines
  • Hallucinogens
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Proto-Oncogene Proteins c-fos
  • Receptors, Serotonin, 5-HT2
  • Serotonin 5-HT2 Receptor Agonists
  • 4-iodo-2,5-dimethoxyphenylisopropylamine

Grants and funding

This work was supported in part by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (B), Grant numbers 21390069 (A.B.), 23790295, 25460100 (AH-T), Grant-in-Aid for JSPS Fellows, Grant number 11J03702 (KH), and the Funding Program for Next Generation World-Leading Researchers, Grant number S22LS0810 (HH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.